Gamida Cell Reports Second Quarter and First Half 2023 Financial Results and Provides Company UpdateBusiness Wire • 08/14/23
Data Published in Transplantation and Cellular Therapy Suggest Antiviral Protection After Transplantation with Gamida Cell's Omisirge® (omidubicel-onlv)Business Wire • 07/11/23
Gamida Cell (GMDA)'s Technical Outlook is Bright After Key Golden CrossZacks Investment Research • 06/09/23
Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare ConferenceBusiness Wire • 05/31/23
Data To Be Presented on Gamida Cell Natural Killer (NK) Cell Therapy Candidate GDA-201 at the International Society for Cell & Gene Therapy 2023 Annual MeetingBusiness Wire • 05/31/23
Gamida Cell Reports First Quarter 2023 Financial Results and Provides Company UpdateBusiness Wire • 05/15/23
Gamida Cell Announces the Date of Its First Quarter 2023 Financial Results and WebcastBusiness Wire • 05/11/23
Gamida Cell's Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA ApprovalBusiness Wire • 04/17/23
Gamida Cell Reports Full Year 2022 Financial Results and Provides Company UpdateBusiness Wire • 03/27/23